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Introduction
The incidence of twin pregnancy is increasing, mainly due to delayed childbirth and advanced maternal age at conception and the extensive use of assisted reproduction techniques (1) . Twin pregnancies are associated with a greater risk of preterm delivery, low birth weight, intrauterine growth restriction (IUGR) and intrauterine fetal death (IUFD). A fivefold increase in the rate of stillbirths is observed in dichorionic twins (DC) compared with singleton pregnancies. Preterm birth occurs in up to 60% of twin pregnancies, contributing to the increased risk of neonatal mortality (2) . The recent global drive to prevent stillbirth has highlighted multiple pregnancy as a major risk factor (2) .
IUGR, strongly associated with fetal demise, is commonly observed in twins, with an incidence of 25-35%, and can affect one or both fetuses. In the IUGR surviving fetuses, a positive correlation between low birth weight, abnormal neurodevelopment and increased risk of adult cardiovascular disease have been documented (3) .
Although the pathogenesis of IUGR is unclear and thus management remains a major challenge, fetoplacental blood vessels are compromised, resulting in altered umbilical artery (Umb art) blood flow in the severest cases.
Severe reduction in Umb art blood flow as reflected by absent or reverse end diastolic velocity (A/REDV) during pregnancy is highly associated with fetal morbility and mortality and expeditious delivery should be contemplated to prevent IUFD.
L-arginine (L-Arg), a precursor for synthesis of vasodilator nitric oxide (NO), has been used to treat IUGR in humans and sheep (4, 5) . While some studies have associated L-arginine supplementation to improved placental blood flow and increased birth weight compared to standard care, other studies including a welldesigned double blinded trial of oral arginine versus placebo failed to show a benefit in fetal growth (6) .
Efforts to develop effective treatments to improve umbilical arteries blood flow and prevent IUGR and IUFD would be of important clinical significance.
In a recent study, pravastatin treatment improved uterine arteries blood flow and pregnancy outcomes in women with obstetric antiphospholipid syndrome and placental insufficiency-related pregnancy complications: preeclampsia and IUGR (7) . Among the many pleiotropic effects attributed to statins, increased nitric oxide (NO) synthesis, vascular dilatation and anti-inflammatory and antithrombotic effects are described (8) . Thus, there is a strong basis for using pravastatin to improve umbilical arteries (Umb Art) blood flow, ameliorate IUGR and protect twin pregnancies. Pravastatin showed not to be teratogenic in mice and women (9) (10) (11) . Five women with twin pregnancies that presented umb art pulsatility index above limits for gestational age and thus at risk of fetal growth restriction and death were treated Larginine and pravastatin. We hypothesized that this combined therapy might have a synergistic modulatory effect on nitric oxide synthesis leading to Umb art vasodilation, blood flow improvement and A C C E P T E D M A N U S C R I P T prevention of growth restriction and IUFD in dichorionic twin pregnancies. In vitro studies, using aortic rings and isolated placental endothelial cells from mice were performed to test to test our hypothesis. 
METHODS

Human studies
Ultrasonography of pregnancies
Doppler examinations were performed by two examiners (AJ and ZJ) using RM6C matrix 4D convex probe (Voluson E10, GE Healthcare) and V4-8 4D convex probe (Medison V20 Prestige, Korea) with the high-pass filter at 60 Hz. Spectral Doppler analysis of flow velocity waveforms in fetal blood vessels (middle cerebral artery, umbilical artery) was performed after obtaining a minimum of 10 heart rate cycles without fetal movement and fetal breathing. When AEDV was detected in umbilical artery, measurements were repeated 3 times on different free loops of umbilical cord.
The following variables were recorded: i) Umbilical artery pulsatility index(Umb Art PI) obtained from a free loop of the umbilical cord; ii) middle cerebral artery (MCA) pulsatility index (PI) measured in the straight portion of the artery avoiding head compression by the transducer and iii) the cerebroplacental ratio (CPR) was calculated as the ratio of the MCA PI divided by the Umb Art PI.
Animal studies
All animal studies were performed in accordance with the 1986 UK Home Office Animal Procedures Act. 
Wire myography
To examine the effects of L-Arg and PRAV on vascular reactivity, aortic rings and wire myography were used (13) . The aorta was dissected, cleaned of surrounding fat, cut into approximately 2.5mm rings and mounted into a chamber unit in a multi-wire myograph system (610M, Danish Nyo Technology, Denmark).
Vessel tension data was recorded and stored on a computer using Myodaq 2.02 analysis software (Danish Nyo Technology, Denmark). Vessels were then left to equilibrate for 30 minutes in physiological salt solution (PSS) and then subject to constriction with 125mM potassium -substituted PSS (KPSS) as previously described (13) . 
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After the experiments, contractile ability of the blood vessels was tested. Vessels which failed to contract to KPSS or phenylephrine were not included in the study.
NO production and synthesis in mouse placentas
The thoracic aorta, a compliance vessel continually subjected to different hemodynamic forces may adjust its vascular tone in a different way to smaller placenta blood vessels. Thus, we investigated NO production in placental blood vessels by measuring eNOS (endothelial NO synthase) synthesis by RT-PCR in endothelial cells isolated from placentas from control mice and mice treated with PRAV, L-Arg and PRAV+L-Arg. In addition, total content of NO was measured in placentas from all experimental groups.
Isolation of placental endothelial cells
Pregnant mice were killed by cervical dislocation. Placentas (4-5 per mouse) from control mice and mice treated with L-Arg, PRAV and PRAV+L-Arg (n=4 mice/experimental group) were dissected (free of umbilical cord and maternal decidua). A single-cell suspension from placental homogenates was obtained by enzymatic dissociation using the gentleMACS Dissociator (Miltenyi Biotec).
CD31/PECAM-1 is mainly expressed on endothelial cells. 2.8 µm superparamagnetic Dynabeads® M-270
Epoxy beads were conjugated with rat monoclonal anti mouse CD31 (ThermoFisher Scientific). The CD31+ cells in the single cell suspension from placentas were magnetically labeled with Dynabeads conjugated with anti CD31 antibodies after incubation with FcR blocking readent (Miltenyi Biotec). Next, the cell suspension was loaded onto a MACS® Column, which was placed in the magnetic field of a MACS Separator (Miltenyi Biotec). The magnetically labeled CD31+ cells were retained within the column. After removing the column from the magnetic field, the magnetically retained CD31+ cells were eluted as the positively selected cell fraction. The CD31+ placenta-derived cells were kept at -80C for further RT-PCR studies.
Because CD31 is also expressed on most leukocytes, these cells were depleted using microbeads conjugated with anti CD45 antibody (monoclonal [I3/2.3] antibody, Abcam) from dissociated primary placental tissue prior to CD31 positive selection. CD31 can also be found on platelets, however immunohistochemical detection of CD42 , marker of platelets, in whole placentas showed extremely low number of platelets in this tissue (data not shown).
Nitric oxide determination in placentas
Placentas were homogenized in isotonic solution of PBS (1:9 W/V) containing 10mM N-ethylmaleimide (NEM) and 2.5 mM EDTA to prevent artefactual formation of NO products or metabolites during sample preparation. Determination of NO was performed indirectly through the spectrophotometric measurement of its stable decomposition products nitrate and nitrite. This method requires that nitrate
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first be reduced to nitrite and then nitrite determined by the Griess reaction. Briefly, the Griess reaction is a two-step diazotization reaction in which the NO-derived nitrosating agent, dinitrogen trioxide (N2O3) generated from the acid-catalyzed formation of nitrous acid from nitrite (or autoxidation of NO) reacts with sulfanilamide to produce a diazonium ion which is then coupled to N-(1-napthyl) ethylenediamine to form a chromophoric azo product that absorbs strongly at 540 nm. A commercially available nitric oxide metabolite detection kit was used (Cayman Chemical, USA)
RNA extraction and quantification of eNOS expression by real-time qPCR
The expression of eNOS in isolated placental endothelial cells was analysed by RT-PCR. RNA from was extracted using Qiagen RNA extraction columns as per the manufacturer's instructions, including initial homogenisation in Trizol (Invitrogen). RNA purity was verified using a nanodrop. 1 μg total RNA was reverse transcribed using a First Strand cDNA Synthesis kit (Fermentas Life Sciences). Relative quantification of gene expression was performed by real-time PCR using iQ SYBR-Green Supermix on the iCycler iQ thermal cycler (BioRad) following the manufacturer's protocols. Primer sequences are: GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used to normalize the quantitative experiments based on prior reference-gene suitability testing and we verified for each experiment that the raw GAPDH values were not significantly different between groups. Primer sequences were as follows:
Mouse GAPDH sense, GGC CTT CCG TGT TCC TAC; antisense, TGT CAT CAT ATC TGG CAG GTT, mouse eNOS sense CCT GGA GGA ATA ATG CTG AAT; antisense, AAT GGT AAC GTG CAG GAC ATC. The relative quantities are expressed as the specific ratio between the gene of interest and the reference gene.
Statistics
All statistical analyses were performed using Prism 6.0 Software (GraphPad Software Inc.).
Comparisons between groups were performed by either one-way analysis of variance (ANOVA) with Dunnett's post hoc test within group and with Bonferroni's post hoc test between groups. In all cases, P ≤ 0.05 were deemed statistically significant. Data are presented as mean ± standard deviation (SD).
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RESULTS
Human studies
Selective increased umbilical artery pulsatility indexes (Umb Art PI) above limits for gestational age were Fig 1 A and B Table 1 , Fig 1A and 1B) . The improvement in Umb Art blood flow was associated with an increase in fetal weight ( Table 1 , Fig 2A) . While fetal weight stagnation is frequently observed in twins with diminished Umb Art blood flow, a significant weight gain was observed in the 5 fetuses after PRAV+L-Arg treatment ( 
Animal studies
In an attempt to understand the mechanism behind the beneficial effects of PRAV+L-Arg in improving umbilical arteries blood flow observed in humans, animal studies were performed.
A C C E P T E D M A N U S C R I P T Synergistic vasorelaxant effect of PRAV+L-Arg
The effects of PRAV, L-Arg and the combined therapy on endothelial and vascular function were measured in aortic rings from pregnant mice using wire myography. Incubation with PRAV induced relaxation of aortic rings preconstricted with NE. PRAV-induced vasodilation was bigger than that elicited by Ach ( Figure   3A ). L-Arg showed a weaker vasorelaxant effect compared to Ach and PRAV (Figure 2A ) . However, aortic rings incubated with PRAV+L-Arg showed enhanced relaxation compared to L-Arg, PRAV or ACh ( Figure   3A ). Removal of the endothelium from the aorta completely prevented relaxation responses to PRAV and L-Arg (data not shown). Relaxation in response to PRAV or L-Arg was abolished by inhibition of NOsynthase (nitro-L-arginine methyl ester L-NAME, 100 μM) ( transmural tension change (%): PRAV+L-NAME= 5.5 3.2, L-Arg+L-NAME 6.82.9) indicating that NO plays a role in the vasorelaxant properties of PRAV and L-Arg. The ex-vivo studies also suggest that NO is an important mediator in PRAV and L-Arg induced vasodilation. Aortic rings from pregnant mice treated with PRAV+L-Arg showed an enhanced NOdependent ACh induced vasorelaxation compared to aortic rings isolated from pregnant mice treated with PRAV or L-Arg alone ( Figure 3B ).
Increased synthesis of eNOS in placental endothelial cells from mice treated with PRAV+L-Arg
RT-PCR studies were used to determine the synthesis eNOS, enzyme that catalyzes the production of nitric oxide (NO) from L-Arg in isolated placental endothelial cells. A five fold increase in gene expression for eNOS was observed in endothelial cells from placentas isolated from L-Arg-treated mice compared to control placentas ( Figure 4A ). PRAV treatment induced an eight fold increase in the synthesis of eNOS compared to control. Provocatively, mice treated with the L-Arg +PRAV showed a twelve fold increase in eNOS synthesis compared to placentas from control animals ( Figure 4B ).
Increased production of NO in placentas from PRAV+L-Arg-treated mice
In agreement with the increased eNOs synthesis observed in placental endothelial cells, increased NO production was measured in whole homogenates ( Figure 4B ) from placentas isolated from PRAV, L-Arg and PRAV+L-Arg mice compared to control mice ( Figure 4B ). The biggest production of NO was observed in the placentas from mice that received the combined treatment PRAV+L-Arg. NO levels in placentas from PRAV+L-Arg-treated mice were higher than those observed in mice that received L-Arg or PRAV alone ( Figure 4B ). We hypothesised that vasorelaxant NO plays an important role in the effects of PRAV+L-Arg in restoring the Umb arteries blood flow and animal studies were performed to test this hypothesis. Indeed, an NOdependent vasorelaxant effect of PRAV and L-Arg was detected in aortic rings from mice using wire myography. Aortic rings from control mice incubated with PRAV, L-Arg and PRAV+L-Arg showed a diminution in the vascular resistance. The vasorelaxant effect was blunted by inhibition of eNOS with L-NAME, demonstrating that an NO-dependent mechanism is involved. A direct vasodilator effect of PRAV on the endothelium in aortic rings was previously reported by Kaesemeyer et al in non pregnant rats (19) .
A C C E P T E D M A N U S C R I P T
In this study, PRAV also induced NO production in cultured bovine aortic endothelial cells (19) . Aortic rings
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from pregnant mice treated with PRAV or L-Arg showed an enhanced Ach-induced vasorelaxation compared to aortic rings isolated from untreated pregnant mice. Dual therapy PRAV+L-Arg induced a much robust vasorelaxant response compared to L-Arg and PRAV alone.
While a vasorelaxant response to L-Arg and PRAV was observed in aortic rings, the aorta is a compliance vessel that may adjust its vascular tone in a different way to smaller placenta blood vessels. Therefore, synthesis of eNOS in endothelial placental cells was studied. It has been shown that eNOS augments fetoplacental blood flow, placental vascularization, and fetal growth in mice (20) . In addition, it has been reported that PRAV protects the endothelium by activating eNOS independent of its cholesterol-lowering actions (21) . Moreover, an increase in the synthesis and activity of eNOS was found in human placental cotyledons perfused with PRAV (22) . Interestingly, it has also been described that L-Arg increases eNOS expression (23) . L-Arg treated rabbits showed increased eNOS expression in aortas (23) . In agreement with the bibliography and the NO-dependent vasorelaxant mechanism identified in aortic rings, increased synthesis of eNOS was detected in placental endothelial cells isolated from mice treated with L-Arg, PRAV and the combined therapy. PRAV+L-Arg induced a more significant increase in eNOS synthesis compared to PRAV and L-Arg alone.
Previous studies from our Laboratory that showed that PRAV restored plasma levels of NO in a mouse model of placental insufficiency (23) . In addition, it has been reported that statins increase eNOS mRNA stability leading to increased eNOS activity (24). Increased eNOS synthesis and activity combined with the increased availability of eNOS substrate L-Arg might result in increased NO generation leading to vasorelaxation of placental vessels.
Pravastatin is a hydrophilic molecule with limited transfer across the placenta. However, the small amount of pravastatin that reachedthe placental fetal vessels (18% of the administered dose (15)) was able to induce relaxation in vitro in the aortic rings. L-Arg alone evoked only minor vasorelaxation in aortic rings with intact endothelium compared to ACh or PRAV. Small relaxations, or absence of relaxations, to L-Arg have also been observed in rat and rabbit aortas and in bovine pulmonary artery and vein (25, 26) . While LArg -induced vasorelaxation in aortic rings was weaker compared to PRAV, the combined therapy induced significant vasorelaxation. The combination of PRAV+L-Arg induced a significant diminution in vessel resistance in the mouse in vitro studies and in the human Doppler studies. The amino acid L-Arg is converted to L-citrulline and NO by NOS and is a limiting factor in NO availability (27) (28) (29) . Positive immunofluorescence for endothelial eNOS was described in human umbilical cord artery (30) . By increasing intracellular endothelial L-Arg stores and enhancing eNOS synthesis and expression, PRAV+L-Arg might synergistically increase NO bioavailability, inducing vasorelaxation and improving umbilical arteries blood flow. We also need to consider that both the endothelial cells and the vascular smooth muscle
possess biochemical pathways converting L-Arg to NO, thus the relaxation of the smooth muscle might also contribute further to the vasorelaxation.
Among many other pleiotropic effects, PRAV showed to increase heme oxygenase/carbon monoxide (CO) production (8) . Interestingly, chronic inhalation of CO, potent vasodilator, throughout gestation showed to increase uterine blood flow in mice (31) . Thus, PRAV-induced CO production might also contribute to the improvement of the blood flow in the umbilical arteries in the twin study.
The combination of PRAV+L-Arg improved Umb art blood flow, increased fetal weight and allowed progression of pregnancy with favorable outcomes in twin pregnancies with discordant umbilical artery resistance. This study provides evidence on the efficacy of PRAV+L-Arg in preventing adverse pregnancy outcomes associated with discordant abnormal Umb artery flow in twins.
Limitations of this study include the small number of patients which means that precise conclusions cannot be draw. Nevertheless, this clinical case report describes and analyzes the successful management of five pregnant patient with twin pregnancies with discordant fetal growth and may constitute the first line of evidence in health care to treat an unusual but serious pregnancy complication. Larger studies would be needed to more clearly demonstrate the beneficial effect of PRAV+L-Arg combination in preventing adverse pregnancy outcomes in twin pregnancies with discordant umbilical artery blood flow and intrauterine growth restriction.
A C C E P T E D M A N U S C R I P T Figure 1 . Umbilical artery pulsatility index during the course of pregnancy in the five patients with twin pregnancy with discordant fetal growth.
The dash line corresponds to the fetuses with compromised umbilical artery flow. The colored arrows indicate the time at which pravastatin +L-arginine treatment was introduced for each patient. B-Doppler ultrasound imaging of umbilical arteries before and after pravastatin + L-arginine treatment (patient 5).
A C C E P T E D M A N U S C R I P T The dash line corresponds to the foetuses that showed compromised umbilical artery flow early in pregnancy. The coloured arrows indicate the time at which pravastatin +L-arginine treatment was introduced for each patient.
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